Document:

Exhibit
10.32

 

CONSULTING
AGREEMENT

 

THIS
CONSULTING AGREEMENT (the “Agreement”), is made and entered into as of the 4th day of August, 2020, by
and between PETER COLE (“Consultant”), and COVISTAT, INC., a Delaware corporation (“Client”) (Consultant
and Client are sometimes collectively referred to as the “parties” and each individually as a “party”).

 

WHEREAS,
the Client is a biosciences company that is engaged in efforts to develop an inhaled nafamostat program (the “Program”);

 

WHEREAS,
Consultant, individually and in his capacity as a founder and owner of Mucokinetica, Ltd. (“Mucokinetica”), is experienced
in the development of respiratory disease treatments;

 

WHEREAS,
Client is party to a Technology Transfer Agreement (the “Transfer Agreement”) with Mucokinetica pursuant to which
Client has agreed to acquire, and Mucokinetica has agreed to sell, rights to certain technologies (the “Mucokinetica Technology”)
developed by Mucokinetica for the treatment of respiratory disease; and

 

WHEREAS,
as a condition of the transfer of the Mucokinetica Technology pursuant to the terms of the Transfer Agreement, Client has undertaken
to retain Consultant and Consultant has agreed to serve on Client’s Scientific Advisory Board and provide consulting services to
Client on the terms described herein.

 

NOW,
THEREFORE, in consideration of the premises above, the mutual promises contained herein, and for other good and valuable consideration,
the parties agree as follows:

 

ARTICLE
1

SERVICES

 

1.1
Advisory Board Service. During the Term, Client shall appoint Consultant, and Consultant shall serve (such service being referred
to as “Advisory Board Service”), as a member of Client’s Scientific Advisory Board.

 

1.2
Consultant Obligations. During the Term, commencing on the Start Date, Consultant agrees to provide drug development and identification
services (the “Consulting Services” and, together with Advisory Board Service, the “Services”),
as requested from time to time by Client, with respect to targeted drug products (the “Targeted Products”) described
on Exhibit A hereto. The “Start Date” shall be the date on which both (i) Client shall have advised Consultant
that Client has secured adequate financing to commence work on its Program; and (ii) Client and Consultant shall have executed Exhibit
B hereto setting forth the Base Consulting Fee.

 

1.3
Manner, Means, Location and Time of Services. Consultant shall devote such time and effort as is necessary to discharge its duties
hereunder and shall exercise reasonable care in the performance of such Services but shall have sole and exclusive discretion and control
with regard to the manner, means, location and time of provision of the Services subject to the right of Client to establish deliverables
and deadlines for Services to be provided.

 

    	1

    	 

    

 

1.4
Client Cooperation; Reliance on Information. As a condition of the provision of Services, Client agrees to fully cooperate with
Consultant in order to facilitate the performance of Services, including providing to Consultant such information as shall be reasonably
necessary to perform the Services. Consultant shall, in the performance of Services, be entitled to rely upon any information provided
by Client and shall be under no obligation to verify the accuracy of any such information.

 

1.5
Nature of Services. Client acknowledges and agrees that Consultant may engage in the development of drugs on its own behalf and
on behalf of other clients and that nothing herein shall prohibit Consultant from engaging in such activities or create rights in Client
with respect to drugs that may be developed as a result of such efforts; provided, however, that, during the Term, Consultant shall not
engage in the development of drugs, on its own behalf or on behalf of parties other than Client, that compete, or could compete, with
the Targeted Products.

 

1.6
Independent Contractor. The parties do not intend for this Agreement to create an agency relationship between Client and Consultant.
Consultant is acting as an independent contractor and is not, and shall not be deemed to be, an employee, agent, partner or affiliate
of Client. Consultant shall not have, and shall not represent that it has, the authority to bind Client or direct any management action
or policy as a result of this agreement or the provision of Services to Client. As Consultant is not an employee of Client, Consultant
is not entitled to any benefits otherwise payable to Client employees and is responsible for paying all required state and federal taxes
and, accordingly, Client will not (i) withhold FICA (Social Security) from payments to Consultant or make FICA contributions on behalf
of Consultant, (ii) make state or federal unemployment insurance contributions on behalf of Consultant, (iii) withhold state or federal
income tax from payments to Consultant, (iv) make disability insurance contributions on behalf of Consultant, or (v) obtain workers’
compensation insurance on behalf of Consultant.

 

ARTICLE
2

CHARGES
AND PAYMENTS

 

2.1
Base Consulting Fee. Client will pay Consultant a “Base Consulting Fee” on the terms set forth on Exhibit
B.

 

2.2
Expenses. Client will reimburse or advance expenses (the “Reimbursable Expenses”) incurred in connection with
performance of the Services if and to the extent, and only if and to the extent, approved in advance in writing by Client.

 

2.3
Out-Licensing Fee. In the event that a Targeted Drug is out-licensed or sold by Client during or following the Term, Client will
pay to Consultant the Out-Licensing Fee as described on Exhibit C.

 

ARTICLE
3

TERM

 

This
Agreement will be effective as of the date herein first set forth (the “Effective Date”), and will continue for a
period of one year (the “Initial Term”). The term of this Agreement shall continue following the Initial Term for
sequential one year terms unless either party shall, not later than thirty (30) days prior to the end of the then current term of this
Agreement, have given notice to other party of termination (as extended from time to time, the “Term”).

 

    	2

    	 

    

 

ARTICLE
4

PROPRIETARY
RIGHTS

 

4.1
Confidential Information. Consultant agrees that at no time (either during or subsequent to the Term of this Agreement) will Consultant
disclose or use, except in pursuit of the business of Client or any of its subsidiaries or affiliates, any Proprietary and Confidential
Information of Client, or any subsidiary or affiliate of Client. The term “Proprietary and Confidential Information”
shall mean, but is not limited to, all information which is known or intended to be known only to Client, its subsidiaries and affiliates,
and their employees, including any document, record, financial or other information of Client, or others in a confidential relationship
with Client, and further relates to specific business matters such as the Client’s financial information, product formulations,
policies and procedures, fee structures, trade secrets, proprietary know-how, account information, and other information relating to
other business of Client, its subsidiaries and affiliates, and their employees. It is specifically acknowledged and agreed that all information
pertaining to the Mocukenitica Patents and the Mucokinetica Technology is Proprietary and Confidential Information, even if such information
was obtained by Consultant prior to the Term of this Agreement. Consultant agrees not to remove from the premises of Client, except as
necessary for Consultant to perform Services in accordance with the terms of this Agreement, any document, record, or other information
of Client or its affiliates.

 

Consultant
agrees to return or destroy, immediately upon termination of Consultant’s Services hereunder, any and all documentation relating
to Proprietary and Confidential Information of Client that is in the possession of Consultant, in whatever format it may be maintained,
whether provided to, or developed by, Consultant, and to provide a certificate of destruction if required by Client.

 

4.2
Ownership of Intellectual Property. The parties acknowledge that Client is the owner of (i) all intellectual property rights created
by Consultant during the Term as part of the Services, and that such works shall be deemed “works made for hire” under copyright
laws and (ii) the Mucokinetica Patents and Mucokinetica Technology (as defined in the Transfer Agreement). The Parties further acknowledge
that, except as provided in the preceding sentence, Consultant shall retain all ownership rights with respect to any intellectual property
created by Consultant during the Term or thereafter that have no connection at all to Client or to the Services provided hereunder or
to the Target Products; provided that the foregoing shall not modify the obligations of Consultant under Section 4.1 above.

 

ARTICLE
5

QUALITY
OF WORK; STANDARD OF CARE; LEGAL COMPLIANCE

 

5.1
Quality of Work. Consultant shall perform the Services in a professional manner, to the best of his ability.

 

5.2
Standard of Care. Consultant shall perform the Services in a diligent, productive and efficient manner as is customary in the
profession of health care research and development.

 

    	3

    	 

    

 

5.3
Compliance With Law. Subject to the foregoing, Consultant shall perform the Services in a manner that complies with applicable
laws in all material respects.

 

ARTICLE
6

MISCELLANEOUS

 

6.1
Force Majeure. Neither party will be liable for any delay or failure of performance (except for the payment of money) affecting
such party or its contractors arising from any cause, circumstance or contingency beyond the reasonable control of such party, including
acts of God, acts of terrorism, governmental acts, accidents, wars, riots or civil unrest, labor disputes, fires, storms, earthquakes,
floods and latent defects which are not reasonably discoverable and cannot be reasonably remedied.

 

6.2
Entire Agreement. Except as otherwise provided herein, this Agreement represents the entire understanding and agreement between
the parties, and supersedes any prior agreement, understanding or communication between the parties, with respect to the subject matter
hereof. This Agreement may only be amended by a writing executed by both parties. In addition, no representation, promise or inducement
has been made by either party that is not embodied in this Agreement, and no party shall be bound by or liable for any alleged representation,
promise or inducement not so set forth.

 

6.3
Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original, and all of which taken
together will constitute a single instrument.

 

6.4
Construction. The parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity
or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties and no presumption
or burden of proof will arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement.

 

6.5
Assignment. This Agreement will be binding on the parties and their respective successors and permitted assigns. Neither party
may, nor will either party have the power to, assign this Agreement or any of its rights and obligations under this Agreement without
the prior written consent of the other party, except that either party may assign, upon written notice to the other party, its rights
and obligations under this Agreement, in whole or in part, without the approval of the other party to any successor in a merger or acquisition
of such party, or an entity that acquires all or substantially all of the assets of such party. In no event will any assignment relieve
the assigning party of its obligations under this Agreement. Any attempted assignment, delegation, or subcontracting in contravention
of this Section will be void and ineffective.

 

6.6
Survival. The provisions of Articles 2.3 and 4 shall survive any termination of this Agreement.

 

6.7
Remedies. In addition to any other remedies Client may have by virtue of this Agreement, Consultant agrees that Client is entitled
to seek equitable relief, including injunctive relief to restrain any breach of the proprietary rights provisions of Article 4 of this
Agreement.

 

    	4

    	 

    

 

6.8
Limitation on Liability. Notwithstanding any other provision of this Agreement, in no event shall either party be liable to the
other for lost profits, or special, incidental, punitive, or consequential damages or costs and attorney’s fees relating to litigation
relating to such losses, costs or damages arising from or relating to this Agreement.

 

6.9
Notices. All notices and other communications hereunder will be in writing and will be deemed given if delivered personally or
by email (receipt verified), or sent by express courier service, to the parties at the following addresses (or at such other address
for a party as will be specified by like notice; provided, that notices of a change or address will be effective only upon receipt thereof):

 

	If
    to Client, addressed to:
	 
	Covistat,
    Inc.
	3210
    Merryfield Row
	San
    Diego, CA 92121
	Attn:
    Dr. Lynn Kirkpatrick
	Email:
    lkirkpatrick@ensysce.com

 

	If
    to Consultant addressed to: 
	 
	Peter
    Cole
	 
	Email:
    peter.cole07@btinternet.com

 

6.10
Waiver. The failure of either party to insist upon the strict and punctual performance of any provision hereof will not constitute
a waiver of, or estoppel against asserting the right to require such performance, nor should a waiver or estoppel in one case constitute
a waiver or estoppel with respect to a later breach whether of a similar nature or otherwise.

 

6.11
Governing Law. All rights and obligations of the parties relating to this Agreement will be governed by and construed in accordance
with the law of the State of California, without giving effect to any choice-of-law provision or rule (whether of the State of California
or any other jurisdiction) that would cause the application of the laws of any other jurisdiction.

 

6.12
No Third Party Beneficiary Status. The terms and provisions of this Agreement are intended solely for the benefit of each party
hereto and their respective successors or permitted assigns, and it is not the intention of the parties to confer third-party beneficiary
rights upon any other party, including employees.

 

    	5

    	 

    

 

IN
WITNESS WHEREOF, each of the parties hereto, by its duly authorized representative, has hereby executed this Consulting Agreement as
of the date herein first set forth.

 

	“CLIENT”	 	“CONSULTANT”
	 	 	 	 
	By:	/s/
    Lynn Kirkpatrick	 	/s/
    Peter Cole
	Name:	Lynn
    Kirkpatrick	 	Peter
    Cole
	Title:
    	CEO	 	 

 

    	6

    	 

    

 

EXHIBIT
A

 

Targeted
Products

 

[omitted]

 

Services

 

[omitted]

 

    	7

    	 

    

 

EXHIBIT
B

 

Base
Consulting Fee

 

[Omitted]

 

    	8

    	 

    

 

EXHIBIT
C

 

Out-Licensing
Fee

 

[Omitted]

 

    	9Exhibit
10.33

 

PROMISSORY
NOTE

 

	Lynn
    Kirkpatrick	 	Date
    of Issuance
	$100,000.00	 	Mar
    16, 2021

 

FOR
VALUE RECEIVED, Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), hereby promises to pay to the order of
Lynn Kirkpatrick (the “Lender”), the principal sum of one hundred thousand dollars ($100,000.00) together with interest on
the unpaid principal balance at the rate on the terms provided for herein.

 

1.
Interest. Simple interest shall accrue on the unpaid principal balance of this Note at the rate of 10% per annum commencing March
16, 2021 until this Note is paid in full. Interest shall accrue and be payable based on the actual number of days elapsed commencing
on the date hereof and ending on the day prior to payment based on a 360-day year.

 

2.
Payment. The principal amount of this Note, together with all accrued and unpaid interest, is payable in full on the earlier of
June 30, 2022 or receipt by the Company, from and after the date hereof, of an aggregate of at least $2,000,000 in gross proceeds from
the sale of any one or more of common stock, preferred stock or any securities convertible into common stock or preferred stock of the
Company. All payments hereunder shall be made in U.S. dollars and applied first to Costs (as defined below), then to accrued and unpaid
interest due and payable and any remainder applied to principal. The Company may prepay this Note at its sole and absolute discretion.
The Company hereby waives demand, notice, presentment, protest and notice of dishonor.

 

3.
Security. This Note is a general unsecured obligation of the Company.

 

4.
Amendments and Waivers. This Note may be amended or waiver of any term of this Note granted only with the written consent of both
parties.

 

5.
Successors and Assigns. This Note applies to, inures to the benefit of, and binds the successors and assigns of the parties hereto;
provided, however, that the Company may not assign its obligations under this Note without the written consent of the Lender.
This Note may be transferred and assigned by the Lender only upon surrender of this Note to the Company and instruction by the Lender
to reissue a new note to the transferee. The Lender and any subsequent holder of this Note receives this Note subject to the foregoing
terms and conditions, and agrees to comply with the foregoing terms and conditions for the benefit of the Company and any other Lenders.

 

6.
Officers and Directors not Liable. In no event shall any officer or director of the Company be liable for any amounts due and
payable pursuant to this Note.

 

7.
Expenses. The Company hereby agrees, subject only to any limitation imposed by applicable law, to pay all expenses, including
reasonable attorneys’ fees and legal expenses, incurred by the holder of this Note in endeavoring to collect any amounts payable
hereunder which are not paid when due, whether by declaration or otherwise (“Costs”). The Company agrees that any delay on
the part of the holder in exercising any rights hereunder will not operate as a waiver of such rights. The holder of this Note shall
not by any act, delay, omission or otherwise be deemed to have waived any of its rights or remedies, and no waiver of any kind shall
be valid unless in writing and signed by the party or parties waiving such rights or remedies.

 

8.
Governing Law. This Note shall be governed by and construed under the laws of the State of California as applied to other instruments
made by California residents to be performed entirely within the State of California.

 

9.
Approval. The Company hereby represents that its board of directors, in the exercise of its fiduciary duty, has approved the Company’s
execution of this Promissory Note based upon a reasonable belief that the principal provided hereunder is appropriate for the Company
after reasonable inquiry concerning the Company’s financing objectives and financial situation. In addition, the Company hereby
represents that it intends to use the principal of this Promissory Note primarily for the operations of its business, and not for any
personal, family or household purpose.

 

	 	ENSYSCE
    BIOSCIENCES, INC.
	 	 	 
	 	By:	/s/
    Lynn Kirkpatrick
	 	Name:	Lynn
    Kirkpatrick
	 	Title:	CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]